Evidence map›Paper›PMID 33104864›Full record

ArticleEuropean journal of nutrition2021

Inulin supplementation ameliorates hyperuricemia and modulates gut microbiota in Uox-knockout mice.

Yingjie Guo, Yanan Yu, Hailong Li, Xueli Ding, Xiaoyu Li, Xue Jing, Jianwei Chen, Guilin Liu, Yuan Lin, Chen Jiang and 4 more

Open access · hybridAbstract read
In one paragraph

Article in European journal of nutrition, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 1 synthesis or guideline pooled it, 197 citations in OpenAlex.

  1. Pooled it
  2. Prebiotic Administration to Chronic Kidney Disease Patients Modifies Their Fecal Microbiome and Host Metabolism.Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · 2026
    Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Biological Characteristics of a ProbioticFoods (Basel, Switzerland) · 2026
    Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Yingjie GuoDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, Shandong, China.
Yanan YuDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, Shandong, China.
Hailong LiInstitute of Metabolic Diseases, Qingdao University, Qingdao, 266003, Shandong, China.
Xueli DingDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, Shandong, China.
Xiaoyu LiDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, Shandong, China.
Xue JingDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, Shandong, China.
Jianwei ChenBGI-Qingdao, BGI-Shenzhen, Qingdao, 266555, Shandong, China.
Guilin LiuBGI-Qingdao, BGI-Shenzhen, Qingdao, 266555, Shandong, China.
Yuan LinDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, Shandong, China.
Chen JiangDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, Shandong, China.
Zhen LiuInstitute of Metabolic Diseases, Qingdao University, Qingdao, 266003, Shandong, China.
Yuwei HeInstitute of Metabolic Diseases, Qingdao University, Qingdao, 266003, Shandong, China.
Changgui LiInstitute of Metabolic Diseases, Qingdao University, Qingdao, 266003, Shandong, China. lichanggui@medmail.com.cn.
Zibin TianDepartment of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, Shandong, China. tianzbsun@163.com.ORCID http://orcid.org/0000-0001-7047-2327
Qingdao University · CNMarine Biology Institute of Shandong Province · CN

Funding

the China Postdoctoral Science Foundation 2017M612221the Key Research and Development Plan of Shandong Province 2018GSF118214the National Natural Science Foundation of China 81970461the Natural Science Foundation of Shandong Province ZR2018MH004
6 · The paper itself

Abstract

purposeInulin is a type of fermentable dietary fiber, which is non-digestible, and can improve metabolic function by modulating intestinal microbiota. This study aimed to evaluate the role of inulin in hyperuricemia and microbial composition of the gut microbiota in a mouse model of hyperuricemia established through knockout of Uox (urate oxidase) gene.

methodsKO (Uox-knockout) and WT (wild-type) mice were given inulin or saline by gavage for 7 weeks. The effect of inulin to combat hyperuricemia was determined by assessing the changes in serum UA (uric acid) levels, inflammatory parameters, epithelial barrier integrity, fecal microbiota alterations, and SCFA (short-chain fatty acid) concentrations in KO mice.

resultsInulin supplementation can effectively alleviate hyperuricemia, increase the expressions of ABCG2 in intestine, and downregulate expression and activity of hepatic XOD (xanthine oxidase) in KO mice. It was revealed that the levels of inflammatory cytokines and the LPS (lipopolysaccharide) were remarkably higher in the KO group than those in the WT group, indicating systemic inflammation of hyperuricemic mice, but inulin treatment ameliorated inflammation in KO mice. Besides, inulin treatment repaired the intestinal epithelial barrier as evidenced by increased levels of intestinal TJ (tight junction) proteins [ZO-1 (zonula occludens-1) and occluding] in KO mice. Moreover, serum levels of uremic toxins, including IS (indoxyl sulfate) and PCS (p-cresol sulfate), were reduced in inulin-treated KO mice. Further investigation unveiled that inulin supplementation enhanced microbial diversity and raised the relative abundance of beneficial bacteria, involving SCFAs-producing bacteria (e.g., Akkermansia and Ruminococcus). Additionally, inulin treatment increased the production of gut microbiota-derived SCFAs (acetate, propionate and butyrate concentrations) in KO mice, which was positively correlated with the effectiveness of hyperuricemia relief.

conclusionsOur findings showed that inulin may be a promising therapeutic candidate for the treatment of hyperuricemia. Moreover, alleviation of hyperuricemia by inulin supplementation was, at least, partially conciliated by modulation of gut microbiota and its metabolites.

Indexed as

Gastrointestinal MicrobiomeHyperuricemiaAnimalsDietary SupplementsInulinMiceMice, KnockoutInulinGut microbiotaHyperuricemiaInflammationIntestinal barrierInulin;Short chain fatty acids

Identifiers

PMID33104864
PMCPMC8137640
OpenAlexW3093775221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.